Last updated: 11/07/2018 07:11:54
Dose ranging pharmacokinetics and pharmacodynamics study with mepolizumab in asthma patients with elevated eosinophils
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A multicenter, open-label, dose ranging study to determine the pharmacokinetics and pharmacodynamics of mepolizumab administered intravenously or subcutaneously to adult asthmatic subjects with elevated blood eosinophil levels
Trial description: A multi-center, randomized, open-label, parallel-group, repeat dose study in asthma patients with elevated eosinophils. Eligible subjects will receive 3 doses (28 days apart) of mepolizumab given intravenous (IV) or subcutaneously (SC). Blood samples for safety, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity analysis, as well as safety/tolerability assessments will be collected throughout the study
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Change from Baseline in blood eosinophil levels at Week 12 (Day 84)
Timeframe: Baseline (Day 1 pre-dose) and Week 12
Area under the blood eosinophil time curve (AUEC) up to Day 84
Timeframe: Days 1, 3, 7, 28, 56, 70 and 84
Maximum change from Baseline in blood eosinophils (Emax)
Timeframe: Days 1, 3, 7, 28, 56, 70, 84, 112 and 140
Time to maximum change in blood eosinophils levels (Tmaxeos)
Timeframe: Days 1, 3, 7, 28, 56, 70, 84, 112 and 140
Number of Participants who Achieved >=50% Eosinophil Repletion by Day 140
Timeframe: Days 1, 3, 7, 28, 56, 70, 84, 112 and 140
Mean area under the plasma-concentration time curve (AUC) following SC and IV administration of mepolizumab
Timeframe: Days 1, 3, 7, 28, 56, 70, 84, 112 and 140
Maximum plasma concentration (Cmax) from pre-dose (Day 1) to Day 140 for mepolizumab
Timeframe: Days 1, 3, 7, 28, 56, 70, 84, 112 and 140
Time to maximum plasma concentration (Tmax) from pre-dose (Day 1) to Day 140 for mepolizumab
Timeframe: Days 1, 3, 7, 28, 56, 70, 84, 112 and 140
Terminal half-life (t½) from pre-dose (Day 1) to Day 140 for mepolizumab
Timeframe: Days 1, 3, 7, 28, 56, 70, 84, 112 and 140
Secondary outcomes:
Number of participants with clinical chemistry parameters outside the normal range following treatment
Timeframe: Baseline (Day 1 pre-dose), Weeks 4, 8, 12 and 20
Number of participants with hematology laboratory parameters outside the normal range at following treatment
Timeframe: Days 1, 3, 7, 28, 56, 70, 84, 112 and 140 (follow-up visit)
Change from Baseline in systolic blood pressure and diastolic blood pressure assessed at Baseline, Day 1, Day 28, Day 56, Day 84, Day 112 and Day 140
Timeframe: Baseline (Day 1 pre-dose) and at Day 1, Day 28, Day 56, Day 84, Day 112 and Day 140
Change from Baseline in heart rate assessed at Baseline, Day 1, Day 28, Day 56, Day 84, Day 112 and Day 140
Timeframe: Baseline (Day 1 pre-dose) and at Day 1, Day 28, Day 56, Day 84, Day 112 and Day 140
Number of participants with levels of anti-mepolizumab antibodies at indicated time points
Timeframe: Day 1, Day 112 and Day 140
Number of participants with the indicated electrocardiogram (ECG) findings at Screening and Day 3
Timeframe: Screening (SCR) and at Day 3
Mean AUC to assess the absolute bioavailability of SC mepolizumab
Timeframe: Days 1, 3, 7, 28, 56, 70, 84, 112 and 140
Mean Dose normalized Cmax ratio to assess the relative bioavailability of SC mepolizumab as compared with IV mepolizumab
Timeframe: Days 1, 3, 7, 28, 56, 70, 84, 112 and 140
Interventions:
Enrollment:
70
Primary completion date:
2012-07-03
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Isabelle J. Pouliquen, Oliver Kornmann, Sharon V. Barton, Jeffrey A. Price, Hector G. Ortega. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53(12):1015-1027.
Medical condition
Asthma
Product
mepolizumab
Collaborators
Not applicable
Study date(s)
February 2011 to March 2012
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
No
- Males or eligible females between 18 and 65 years of age inclusive, at the time of signing the informed consent;
- Non-childbearing potential is defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<147 pmol/L) is confirmatory]. To be eligible for entry into the study, females of child-bearing potential and females whose menopausal status is in question must commit to consistent and correct use of an acceptable method of birth control as defined in Section 7.1.1 from one month prior to the first dose of investigational product until 4 months after the last dose of investigational product.
- QTcF ≥450 msec; or QTcF ≥ 480 msec in subjects with Bundle Branch Block.
- AST, ALT, alkaline phosphatase and bilirubin ≥ 1.5xULN (isolated bilirubin <1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin ≥35%).
Inclusion and exclusion criteria
Inclusion criteria:
- Males or eligible females between 18 and 65 years of age inclusive, at the time of signing the informed consent; Non-childbearing potential is defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<147 pmol/L) is confirmatory]. To be eligible for entry into the study, females of child-bearing potential and females whose menopausal status is in question must commit to consistent and correct use of an acceptable method of birth control as defined in Section 7.1.1 from one month prior to the first dose of investigational product until 4 months after the last dose of investigational product. -History of asthma for at least one year. -Subjects must be on a stable dose of an inhaled corticosteroid or combination (ICS+LABA) therapy for at least 12 weeks prior to screening. -FEV1≥45% and <90 % of predicted normal value during screening (obtained between 6:00 AM and 1:00 PM). -Evidence of airway reversibility (FEV1≥12%) within 30 minutes of inhalation of albuterol OR airway hyperresponsiveness (PC20 of <8mg/mL or PD20 of <7.8 µ mol methacholine/histamine) documented in the 12 months prior to randomization. -Subjects with documented evidence of elevated blood eosinophilia levels (>0.3 cells 109/L) within 12 months of screening and evidence of elevated blood eosinophilia levels (>0.3 cells 109/L) at screening. -Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Exclusion criteria:
- QTcF ≥450 msec; or QTcF ≥ 480 msec in subjects with Bundle Branch Block. -AST, ALT, alkaline phosphatase and bilirubin ≥ 1.5xULN (isolated bilirubin <1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin ≥35%). -Subjects with elevated blood eosinophil levels which is not related to asthma -Current smokers (any subject who has smoked within the six months prior to screening or has a positive urine cotinine at screening) or subjects with a smoking history of >10 pack years calculated as follows: Number of cigarettes per day X number of years smoked 20 -Presence of a clinically important lung condition other than asthma including current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, Churg-Strauss syndrome, or diagnoses of emphysema or chronic bronchitis (chronic obstructive pulmonary disease other than asthma) or a history of lung cancer. -An asthma exacerbation or respiratory tract infection within six weeks prior to screening (an exacerbation is defined as worsening asthma requiring the use of systemic corticosteroids and/or emergency department visit, hospitalisation). -Subjects with a parasitic infestation within six months of screening. -A current malignancy or previous history of cancer in remission for less than five years prior screening (except for localized carcinoma of the skin that has been resected for cure). -Subjects who have clinically significant cardiovascular, endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological or any other system abnormalities that are uncontrolled with standard treatment. -Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice), cirrhosis, and known biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones). -Subjects with a known immunodeficiency (e.g. human immunodeficiency virus – HIV). -A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within three months of screening. -Subjects who have received omalizumab [Xolair] within 130 days of administration of the first dose of study medication. -Subjects with recent history (within two years prior to screening) of alcohol misuse or substance abuse prior screening. -A positive pre-study drug/alcohol test at screening. -The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, five half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). -Subjects who have previously participated in a study of mepolizumab and received study medication within 90 days prior to screening. -Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within seven days (or 14 days if the drug is a potential enzyme inducer) or five half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. -Exposure to live vaccine within the four weeks prior to screening and no intention to receive live vaccine during the study. -History of sensitivity to the study medications (or components thereof) or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. -Pregnant or lactating females; pregnancy as determined by positive pregnancy test at screening or prior to dosing.
Trial location(s)
Location
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27103
Status
Study Complete
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
Status
Study Complete
Location
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39112
Status
Study Complete
Location
GSK Investigational Site
Frankfurt am Main, Hessen, Germany, 60596
Status
Study Complete
Showing 1 - 6 of 12 Results
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2012-07-03
Actual study completion date
2012-07-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website